Navigation Links
Swiss agency approves clinical trial of UCI-created neural stem cell therapy
Date:12/7/2010

A therapy developed by Aileen Anderson and Brian Cummings of UC Irvine's Sue and Bill Gross Stem Cell Research Center in collaboration with researchers at StemCells Inc. will be the basis of the world's first clinical trial using human neural stem cells to treat spinal cord injury.

Swissmedic, the Swiss regulatory agency for therapeutic products, has authorized a Phase I/II clinical trial for chronic spinal cord injury, cases in which inflammation has stabilized and recovery has reached a plateau.

The trial will utilize StemCells Inc.'s proprietary purified human neural stem cells and will be conducted at the University of Zurich's University Hospital Balgrist, one of the world's leading medical centers for spinal cord injury and rehabilitation.

It's designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are between three and 12 months post-injury at the time of transplantation. Enrollment is expected to begin in early 2011.

"This is tremendously exciting news," said Anderson, UCI associate professor of physical medicine & rehabilitation and anatomy & neurobiology. "Human neural stem cells may hold great promise for helping people with spinal cord injuries regain lost function."

In their collaboration with StemCells Inc., Anderson and Cummings conducted eight years of preclinical studies in rodents that demonstrated the significant therapeutic potential of human neural stem cells.

Their efforts have shown how these cells, when transplanted into damaged spinal columns, can differentiate into neural tissue cells such as oligodendrocytes and early neurons and migrate to injury sites. In recent studies, the researchers found that the treatment restored hind-limb function in mice when transplanted in the early chronic period after spinal cord injury.

Other stem cell studies have focused on the acute, or early, phase of spinal cord injury, a period
'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Jion Beijing Great Wall International Travel Agency Immediate Exposure to China Expo 2010
2. Home Health Agency Owner Pleads Guilty in Connection with Detroit Fraud Scheme
3. MARC Coalition Applauds Agencys Alert Regarding Delay in Data Exchange Deadline
4. Aid Agency World Vision Granted $19m From USAID/OFDA for Haiti
5. Nurse Staffing Agency, FlexRN, Unveils New Corporate Branding & Website
6. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
7. USHEALTH Career Agency Announces Americas Choice
8. Lloyds of London News Features New Life Agency, Inc.
9. Savannah, Georgia, Insurance Agency Celebrates Over 30 Years of Service
10. The European Medicines Agency Completes Validation Stage for InterMunes Marketing Authorization Application for pirfenidone
11. Agency Pioneer SVH Tours & Travel Launches AppleSpecials.com, New Travel Booking Web Site that Showcases First-Hand Videos and Last Minute Specials
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Swiss agency approves clinical trial of UCI-created neural stem cell therapy
(Date:4/18/2014)... What,s one of your worst memories? How did it ... felt during a negative personal experience, such as how ... lead to emotional distress, especially when you can,t stop ... creep up, thinking about the context of the memories, ... and effective way to alleviate the negative effects of ...
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... scientists at SUNY Downstate Medical Center in Brooklyn and ... patent for their virtual telemicroscope. This patented software permits ... patients living in remote locations around the world. ... pathology at SUNY Downstate, and Jiang Gu, MD, PhD, ...
... on investigations, -- Three-fifths want high school ... stats and awards from guilty pro,athletes, FAIRFIELD, ... Baseball season-opener approaches, a new national poll,indicates that ... use among,professional athletes., On average, Americans polled ...
... DIEGO, March 27 Gen-Probe Incorporated,(Nasdaq: GPRO ) ... Leerink,Swann "Bugs and Drugs: The Future of Molecular Diagnostics ... approximately 1:20 p.m. Eastern,Time. The presentation is scheduled to ... on the investor information section of Gen-Probe,s website,at ...
... physical disability does, study shows , , THURSDAY, March 27 (HealthDay ... almost as often as physical disability does, Australian researchers report. ... 55, who had paying jobs before a stroke found that ... about the same ratio as in a recent U.S. study, ...
... 27 The Anthem Blue Cross and Blue Shield,Foundation announced ... San Luis,Valley Chapter of the American Red Cross to assist ... bottles, formula and water,and to aid volunteers who are distributing ... been affected by the recent Salmonella water,contamination., "One of ...
... dairy cow is back at her Kansas farm ... surgery performed at Kansas State University,s,Veterinary Medical Teaching ... the veterinary students assigned to,her case, sustained a ... in her right knee ruptured. Dr. David Anderson, ...
Cached Medicine News:Health News:SUNY researcher issued patent for virtual telemicroscope 2Health News:Americans Guess One-Third of Professional Athletes on Performance Enhancing Drugs 2Health News:Americans Guess One-Third of Professional Athletes on Performance Enhancing Drugs 3Health News:Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference 2Health News:Depression After Stroke Can Be Debilitating 2Health News:Anthem Blue Cross and Blue Shield Foundation Donates $7,500 to San Luis Valley American Red Cross to Assist Residents Affected by Water Contamination Crisis 2Health News:'Wildcat Power Cord' Repairs Cruciate Ligament in Dairy Cow's Knee 2Health News:'Wildcat Power Cord' Repairs Cruciate Ligament in Dairy Cow's Knee 3
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... February 15, 2012 It has become common ... to be required to submit to random drug screens as ... this billable procedure is to prevent and reduce opioid associated ... the efficacy of drug testing people with chronic pain.   ...
... N.J., Feb. 15, 2012  Omthera Pharmaceuticals, Inc., a ... Jerry Wisler, President and Chief Executive Officer, will present ... Thursday, February 16, 2012 at 3:20 p.m. EST.  He ... on February 29, 2012 at 11:00 a.m. EST.  Both ...
Cached Medicine Technology:New Evidence Points to a "Profits Over Efficacy" Approach to Drug Testing 2Omthera Pharmaceuticals, Inc. to Present at Leerink Swann 2012 Global Healthcare Conference and Citi 2012 Global Healthcare Conference 2
... system builds on the basic infrastructure ... in the system are networked to ... Windows® operating system, which monitors system ... personal computer, RoamAlert Integrity provides reporting ...
... Awarix provides an enterprise visibility ... throughput, improve caregiver effectiveness, and increase ... edge RFID location systems and geospatial ... systems to create a real time ...
MONOJECT MAGELLAN Safety Blood Collection Needle...
This is adapted to microplate or card....
Medicine Products: